2. Protein Tyrosine Kinase/RTK Metabolic Enzyme/Protease Stem Cell/Wnt JAK/STAT Signaling PI3K/Akt/mTOR MAPK/ERK Pathway Apoptosis
  3. PDGFR Carbonic Anhydrase STAT Akt ERK Apoptosis Caspase
  4. PDGFRA/CAIX/XII-IN-1

PDGFRA/CAIX/XII-IN-1 is an inhibitor of PDGFRA, CA IX and CA XII, with an IC50 of 20 nM against PDGFRA, a Ki of 93.3 nM against CA IX, and a Ki of 80.0 nM against CA XII. PDGFRA/CAIX/XII-IN-1 binds to the ATP-binding pocket of PDGFRA and blocks the downstream STAT3, AKT and ERK1/2 signaling pathways. PDGFRA/CAIX/XII-IN-1 induces G0/G1 cell cycle arrest and endogenous apoptosis (Apoptosis), including cleavage of PARP-1, caspase-9 and caspase-3, activation of caspase 3/7, and down-regulation of Mcl-1. PDGFRA/CAIX/XII-IN-1 exhibits antiproliferative activity in eosinophilic leukemia cells. PDGFRA/CAIX/XII-IN-1 can be used for the research of leukemia.

For research use only. We do not sell to patients.

PDGFRA/CAIX/XII-IN-1

PDGFRA/CAIX/XII-IN-1 Chemical Structure

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 Customer Validation

PDGFRA/CAIX/XII-IN-1 Related Antibodies

Top Publications Citing Use of Products

View All PDGFR Isoform Specific Products:

View All Isoforms
PDGFR PDGFRβ PDGFRα

View All Carbonic Anhydrase Isoform Specific Products:

View All Isoforms
CA CA I CA Ⅱ CA IX CA XII CA VII CA VI CA VA CA VB CA XIII CA XIV

View All STAT Isoform Specific Products:

View All Isoforms
STAT3 STAT5 STAT6 STAT1

View All Akt Isoform Specific Products:

View All Isoforms
Akt Akt1 Akt2 Akt3

View All ERK Isoform Specific Products:

View All Isoforms
ERK ERK1 ERK2 ERK5 ERK8

View All Caspase Isoform Specific Products:

View All Isoforms
Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

PDGFRA/CAIX/XII-IN-1 is an inhibitor of PDGFRA, CA IX and CA XII, with an IC50 of 20 nM against PDGFRA, a Ki of 93.3 nM against CA IX, and a Ki of 80.0 nM against CA XII. PDGFRA/CAIX/XII-IN-1 binds to the ATP-binding pocket of PDGFRA and blocks the downstream STAT3, AKT and ERK1/2 signaling pathways. PDGFRA/CAIX/XII-IN-1 induces G0/G1 cell cycle arrest and endogenous apoptosis (Apoptosis), including cleavage of PARP-1, caspase-9 and caspase-3, activation of caspase 3/7, and down-regulation of Mcl-1. PDGFRA/CAIX/XII-IN-1 exhibits antiproliferative activity in eosinophilic leukemia cells. PDGFRA/CAIX/XII-IN-1 can be used for the research of leukemia[1].

IC50 & Target[1]

CA IX

93.3 nM (Ki)

CA XII

80 nM (Ki)

STAT3

 

ERK1

 

ERK2

 

Caspase-9

 

Caspase 3

 

In Vitro

PDGFRA/CAIX/XII-IN-1 (Compound 9d) potently inhibits recombinant PDGFRA protein, with an IC50 of 20 nM[1].
PDGFRA/CAIX/XII-IN-1 (1 μM) exerts targeted inhibitory effects on specific RTK subfamilies, and exhibits potent activity against PDGFRα and closely related class III RTKs[1].
PDGFRA/CAIX/XII-IN-1 inhibits recombinant human cancer-associated CA IX (Ki = 93.3 nM) and CA XII (Ki = 80.0 nM) with moderate potency, while exhibiting only weak activity against normal CA I/II isoforms[1].
PDGFRA/CAIX/XII-IN-1 (72 h) potently inhibits the proliferation of FIP1L1-PDGFRA-driven EOL-1 eosinophilic leukemia cells (GI50 = 2 nM), also exhibits significant cytotoxicity against MV4-11 cells (GI50 = 0.263 μM), and shows weak cytotoxicity against Kasumi-1 and RS4-11 cells with GI50 values of 2.081 μM and 4.599 μM, respectively[1].
PDGFRA/CAIX/XII-IN-1 (0-2500 nM; 1 h) dose-dependently inhibits the phosphorylation of FIP1L1-PDGFRA and its downstream STAT3, AKT and ERK1/2 signaling pathways in EOL-1 cells; after treatment at a concentration of 100 nM for 1 h, the inhibitory effect on PDGFRA is nearly complete[1].
PDGFRA/CAIX/XII-IN-1 (0-2500 nM; 24 h) induces apoptosis in EOL-1 eosinophilic leukemia cells by activating the intrinsic apoptotic pathway. The effect is detectable at a concentration of 0.8 nM, and the pathway is potently activated at subnanomolar concentrations, while no pro-apoptotic effect is observed on THP-1 cells[1].
PDGFRA/CAIX/XII-IN-1 (0.16-100 nM; 24 h) induces dose-dependent G0/G1 cell cycle arrest in EOL-1 eosinophilic leukemia cells, with a significant arrest effect observed at 0.8 nM; additionally, after 24 h of treatment, concentrations of 4 nM and above induce apoptotic cell death (characterized by a sub-G1 cell population)[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

PDGFRA/CAIX/XII-IN-1 Related Antibodies

Western Blot Analysis[1]

Cell Line: EOL-1 cells
Concentration: 0, 4, 20, 100, 500, 2500 nM
Incubation Time: 1 h
Result: Induced a dose-dependent inhibition of FIP1L1-PDGFRA phosphorylation (p-PDGFRA/B Y849/857), with substantial reduction at 20 nM and near-complete dephosphorylation at 100 nM.
Reduced phosphorylation of downstream signaling molecules STAT3 (p-STAT3 Y705) from 20 nM upward, AKT (p-AKT S473) with substantial inhibition at 100 nM and above, and ERK1/2 (p-ERK1/2 T202/Y204) with strong inhibition from 100 nM.
Maintained unchanged total protein levels of PDGFRA, STAT3, AKT, and ERK1/2.

Apoptosis Analysis[1]

Cell Line: EOL-1 cells, THP-1 cells
Concentration: 0.032, 0.16, 0.8, 4, 20, 100, 500 2500 nM (caspase 3/7 activity, Western blot); 0.16, 4, 100 nM (Annexin V/PI staining)
Incubation Time: 24 h
Result: In EOL-1 cells: induced dose-dependent cleavage of PARP-1 (detectable at 0.8 nM, accumulating at 4 nM and higher), reduced antiapoptotic Mcl-1 expression (substantial reduction at 4 nM, near-complete depletion at 20 nM), activated caspase 9 (cleavage detected at 4 nM and higher) and caspase 3 (cleavage detected at 4 nM and higher).
Caused a robust, dose-dependent increase in caspase 3/7 activity (significant activation at 0.032 nM, ~7-fold increase at 0.8 nM).
Induced a concentration-dependent shift from viable cells to early and late apoptotic populations via Annexin V/PI staining.
In THP-1 cells: showed no significant signs of apoptosis or caspase 3/7 activation at tested concentrations.

Cell Cycle Analysis[1]

Cell Line: EOL-1 cells
Concentration: 0.16, 0.8, 4, 20, 100 nM
Incubation Time: 24 h
Result: Caused a dose-dependent accumulation of cells in the G0/G1 phase, accompanied by a decrease in S and G2/M populations.
Induced modest G0/G1 arrest at 0.16 nM, significant arrest at 0.8 nM and higher.
Triggered a sub-G1 apoptotic population from 4 nM onward, which expanded markedly at 20 and 100 nM.
Molecular Weight

507.56

Formula

C25H25N5O5S
Appearance

Solid

SMILES

O=C(NC1=CC(S(=O)(N)=O)=C(C=C1)C)NC2=CC=C(C=C2)NC3=C4C=C(C(OC)=CC4=NC=C3)OC
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 8.75 mg/mL (17.24 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.9702 mL 9.8511 mL 19.7021 mL
5 mM 0.3940 mL 1.9702 mL 3.9404 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
Purity & Documentation

Purity: 98.10%

COA (248 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.9702 mL 9.8511 mL 19.7021 mL 49.2553 mL
5 mM 0.3940 mL 1.9702 mL 3.9404 mL 9.8511 mL
10 mM 0.1970 mL 0.9851 mL 1.9702 mL 4.9255 mL
15 mM 0.1313 mL 0.6567 mL 1.3135 mL 3.2837 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

PDGFRA/CAIX/XII-IN-1 Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

PDGFRA/CAIX/XII-IN-1PDGFRCarbonic AnhydraseSTATAktERKApoptosisCaspasePlatelet-derived growth factor receptorCarbonate dehydratasePKBProtein kinase BExtracellular signal regulated kinasesPDGFRA/CA IX/CA XII inhibitorleukemiaEOL-1 cellsTHP-1 cells
Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
PDGFRA/CAIX/XII-IN-1
Cat. No.:
HY-181587
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.